KemPharm, Inc. (NASDAQ:KMPH) has been assigned a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $9.00.

KMPH has been the topic of several research reports. Roth Capital initiated coverage on KemPharm in a report on Wednesday, June 28th. They set a “buy” rating and a $8.00 price objective on the stock. Royal Bank Of Canada set a $8.00 price objective on KemPharm and gave the stock a “buy” rating in a report on Wednesday, April 12th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of KemPharm in a report on Wednesday, March 22nd. Zacks Investment Research raised KemPharm from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a report on Tuesday, March 14th. Finally, Canaccord Genuity set a $7.00 price objective on KemPharm and gave the stock a “buy” rating in a report on Sunday, March 12th.

In related news, CEO Travis C. Mickle purchased 8,000 shares of the stock in a transaction that occurred on Tuesday, June 20th. The shares were purchased at an average price of $3.45 per share, with a total value of $27,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,629,612 shares in the company, valued at approximately $5,622,161.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders have purchased 10,775 shares of company stock worth $38,783. Corporate insiders own 22.80% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new position in KemPharm during the first quarter worth about $647,000. Morgan Stanley raised its position in KemPharm by 486.9% in the first quarter. Morgan Stanley now owns 30,978 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 25,700 shares in the last quarter. C WorldWide Group Holding A S raised its position in KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock worth $890,000 after buying an additional 16,699 shares in the last quarter. Creative Planning raised its position in KemPharm by 2.3% in the first quarter. Creative Planning now owns 453,723 shares of the specialty pharmaceutical company’s stock worth $2,223,000 after buying an additional 10,200 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares in the last quarter. 42.11% of the stock is currently owned by hedge funds and other institutional investors.

Shares of KemPharm (NASDAQ:KMPH) traded up 2.50% on Monday, reaching $4.10. The company had a trading volume of 11,541 shares. The firm’s market capitalization is $60.05 million. KemPharm has a 12 month low of $2.90 and a 12 month high of $5.50. The firm’s 50 day moving average is $3.91 and its 200 day moving average is $3.89.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.21. On average, equities research analysts expect that KemPharm will post ($2.82) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/03/kempharm-inc-kmph-receives-consensus-recommendation-of-hold-from-brokerages.html.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.